DelfaGLP-1 Atlas

Lead sponsor

Yale University

10 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

10

Trials led

4

Active

372

Total enrollment

14

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Early Phase 1
1
Phase 1
4
Phase 2
4
Phase 4
1

Trials by status

Recruiting
3
Active, not recruiting
1
Completed
4
Terminated
1
Withdrawn
1

Trials led

GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and WeightBMI 30-49.9Ph 1Completed96
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I DiabetesHbA1c 6.5-9.5%Ph 2Completed79
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver DiseaseBMI ≥85Ph 2Active, not recruiting60
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity TreatmentBMI ≥30Ph 2Recruiting54
HARP—Ph 2Recruiting30
Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes—Ph 1Completed17
Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.BMI 18.5-24.9Early Ph 1Terminated13
GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration—Ph 1Completed13
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)BMI ≥30Ph 1Recruiting10
The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young AdultsBMI ≥97Ph 4Withdrawnnot disclosed